Trabectedin in advanced synovial sarcomas: A multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

Anti-Cancer Drugs

Volumn 26, Issue 6, 2015, Pages 678-681

  Sanfilippo, Roberta ^a   Dileo, Palma ^a,f   Blay, Jean Yves ^h   Constantinidou, Anastasia ^g   Le Cesne, Axel ⁱ   Benson, Charlotte ^g   Vizzini, Laura ^b   Contu, Marianna ^c   Baldi, Giacomo G ^d   Dei Tos, Angelo P ^e   Casali, Paolo G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Department of Oncology   (Italy)

^c SS Annunziata Hospital   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e General Hospital of Treviso   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g Sarcoma Unit   (United Kingdom)

^h CENTRE LÉON BÉRARD   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

chemotherapy; soft tissue sarcoma; synovial sarcoma; trabectedin

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SYNOVIAL SARCOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SARCOMA, SYNOVIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DIOXOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA, SYNOVIAL; TETRAHYDROISOQUINOLINES;

EID: 84930590633     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000228     Document Type: Article

References (18)

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization classification of tumours of bone and soft tissue. Lyon, France: IARC; 2013.
2. ESMO/European Sarcoma NetworkWorking Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3):iii102-iii112.
3. Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, Brennan MF. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18:2087-2094.
4. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269-1275.
5. Le Cesne A, Antoine E, Spielmann M, le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13:1600-1608.
6. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73:2506-2511.
7. Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
8. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188-4196.
9. Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol 2010; 22:342-346.
10. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492.
11. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006; 42:1484-1490.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Le Cesne A, Blay JY, Judson I, van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.
14. Panagopoulos I, Mertens F, Isaksson M, Mandahl N. A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun 2000; 279:838-845.
15. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene 2014; 33:5201-5210.
16. Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, et al. A retrospective analysis of antitumour activity with trabectedin in translocationrelated sarcomas. Eur J Cancer 2012; 48:3036-3044.
17. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014; 50:1137-1147.
18. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014; 11:187-202.